On November 12, 2025, President Trump signed H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37). Section 781 of Division B narrows the federal definition of hemp and was set to take full effect on a single date: November 12, 2026. That single-deadline picture is no longer accurate. On September 2, 2026, the President signed H.R. 6500, the Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103), whose Section 2019 pushes most of Section 781 to December 11, 2026 — while leaving a narrower slice of it in place on the original November 12 date. Operators now have two federal clocks to plan against, and which one applies to a given product depends on the cannabinoid inside it, not the product category.
Informational only. This is not legal or tax advice — talk to your counsel.
| Product category | Which date applies | What changes on that date | What to do before it |
|---|---|---|---|
| THC-O acetate | November 12, 2026 | Excluded from "hemp" as a cannabinoid not capable of being naturally produced by the plant; becomes a Schedule I controlled substance | Treat as already scheduled — pull or reformulate now |
| HHC (hydrogenated) | November 12, 2026 | Same exclusion — commercial HHC requires hydrogenation the plant does not perform | Same as THC-O; document that any HHC in inventory cannot be characterized as plant-derived |
| Delta-8 THC (CBD-converted) | November 12, 2026 | Falls under the "cannot be naturally produced" exclusion alongside HHC and THC-O — virtually all commercial delta-8 is isomerized/converted from CBD in a reactor, a synthesis process; the molecule's trace natural occurrence in the plant does not change how the commercial product was actually made | Treat as already scheduled for November 12 — pull, reformulate, or document genuinely plant-extracted (not converted) sourcing if you believe your product is the narrow exception |
| THCA flower and high-THCA products | December 11, 2026 | Total-THC test applies (delta-9 plus 0.877 × THCA); most flower fails the 0.3% dry-weight standard | Re-test under the total-THC method; plan sell-through, reformulation, or exit |
| Delta-9 finished beverages and edibles | December 11, 2026 | 0.4 mg total-THC-per-container cap applies | Reformulate to the cap; confirm container size against FDA's forthcoming definition |
| Non-intoxicating CBD (trace THC) | December 11, 2026, in theory | Same 0.4 mg cap technically applies to any finished product with measurable total THC | Confirm your COA reports total THC, not delta-9 alone, below 0.4 mg per container |
The 2018 Farm Bill defined hemp as cannabis with a delta-9 THC concentration of not more than 0.3 percent on a dry weight basis. That definition, codified in the Agricultural Marketing Act, created the legal foundation for the entire hemp-derived cannabinoid market: CBD products, delta-8 THC, delta-10 THC, HHC, THCA flower, and a range of other products that could claim legal status under the hemp umbrella.
Section 781 of P.L. 119-37 narrows that definition in three ways: it replaces the delta-9-only test with a total-THC standard (delta-9 plus 0.877 times THCA, plus any other cannabinoid HHS designates as having similar effects); it caps finished hemp-derived cannabinoid products at 0.4 milligrams of total THC per container; and it excludes from "hemp" any cannabinoid that is either not capable of being naturally produced by the plant or that was synthesized or manufactured outside the plant. Because the Controlled Substances Act excludes "hemp" by cross-referencing the Agricultural Marketing Act definition, any narrowing of that definition pushes affected products back into CSA Schedule I without separate DEA rulemaking.
As Arnold & Porter noted in December 2025, the change effectively reclassifies many hemp-derived intoxicating THC products as controlled substances once the effective date arrives — and, as of September 2026, there are two effective dates rather than one.
H.R. 6500 funds the government through December 11, 2026, and in a sixty-word section — Section 2019 of P.L. 119-103 — moves most of the federal hemp redefinition to the same day. Section 2019 provides that until December 11, 2026, the Section 781 amendments "shall only apply with respect to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of section 297A" of the Agricultural Marketing Act — the paragraphs covering cannabinoids "not capable of being naturally produced by a Cannabis sativa L. plant." Those products keep the original November 12, 2026 date. Everything else in Section 781 — the total-THC redefinition, the 0.4 mg cap, and the separate exclusion for cannabinoids the plant can produce but that were synthesized or manufactured outside it — now takes effect December 11, 2026.
THC-O acetate is the clearest November 12 case: the acetylation step does not occur in the plant under any circumstance. HHC is the other clear case — commercial HHC is produced by hydrogenation, a reaction the plant does not perform, so regulators are expected to treat it as not naturally producible. Delta-8 THC belongs in the same November 12 category, despite a wrinkle the other two don't have: the delta-8 molecule can occur naturally in the plant in trace amounts. That trace provenance does not change the legal analysis, because virtually all commercially sold delta-8 is not extracted from the plant at those trace levels — it is manufactured by isomerizing or converting CBD in a reactor, a synthesis process. The statutory test turns on how the commercial product was actually made, not on whether the molecule can theoretically occur in nature, so CBD-converted delta-8 falls under the "cannot be naturally produced [at the levels sold]" paragraph alongside HHC and THC-O, on the original November 12, 2026 date. Operators who can document genuinely plant-extracted delta-8 — not chemically converted — are the narrow exception and should confirm that classification with counsel. Our comparisons of HHC vs THC and THCA vs THC walk through how each cannabinoid is classified, and the full mechanics of the delay are in our December 11 delay explainer.
Section 781 also directed the FDA to publish a list of known cannabinoids within 90 days of enactment. That deadline was February 2026. The FDA missed it, and as of this writing has not published the list that would resolve, compound by compound, which cannabinoids the agency considers naturally producible.
In March 2026, the FDA submitted a CBD Products Compliance and Enforcement Policy to the Office of Management and Budget for review. Once finalized, this enforcement policy will likely be the primary guidance document for operators navigating the transition, including how "container" is defined for purposes of the 0.4 mg cap.
THC-O, HHC, and delta-8 THC products. These sit in the "cannot be naturally produced [as sold]" category and should be planned against November 12, 2026, regardless of what happens to the rest of Section 781. Commercial delta-8 belongs here because it is manufactured by converting CBD rather than extracted from the plant's trace natural supply — the molecule's trace natural occurrence does not change how the commercial product is actually made.
Delta-10 THC products. Classification is a factual question the statute does not resolve by name, and state-level restrictions in many states already apply independently of the federal date.
THCA flower. Products marketed as hemp flower with high THCA concentrations that convert to delta-9 THC when heated fail the December 11 total-THC test at the 0.877 conversion factor in the large majority of cases.
High-potency CBD and delta-9 beverages with measurable THC. The 0.4 mg per-container cap, effective December 11, is a milligram test, not a concentration test — a large-format product well under 0.3% can still exceed 0.4 mg in absolute terms.
As Frier Levitt's analysis explained, the redefinition creates compliance complexity that extends beyond product formulation to labeling, marketing claims, and distribution agreements — complexity that the two-date split has only added to.
Ingredient suppliers providing hemp-derived cannabinoid extracts will need to certify not just cannabinoid content but synthesis route — whether a compound was extracted from plant biomass or produced by chemical conversion — since that fact now determines which federal date applies. Existing supply agreements may not contain representations specific enough to cover this. Operators should review supplier contracts for cannabinoid specification clauses and determine whether amendments are needed.
Distribution partners, particularly those in states where intoxicating hemp products are currently legal, face their own compliance assessments on their own timelines. Payment processors and carriers have in some cases set deadlines earlier than either federal date; do not assume a private counterparty will wait for December 11.
Map every product against both dates. For each cannabinoid, document whether it can be produced by the plant, whether your supply is plant-extracted or synthesized, and which of the two paragraphs of Section 2019 it falls under. For anything you cannot document, plan to the more conservative November 12 date.
Testing needs to report total THC, not delta-9 alone, and to state milligrams per innermost container, not concentration. Certificates of analysis generated under the old delta-9-only method will not satisfy either federal date.
Federal timing does not suspend state law. Virginia's 2 mg total-THC per-package cap has been in force since August 15, 2026 — weeks ahead of either federal date, and backed by a dedicated state enforcement unit. Ohio presents the opposite pattern: its SB 56 hemp beverage ban was enjoined for ten specific companies, producing a split market inside one state. A national operator is running several compliance floors at once, and the federal date is only the one that applies everywhere.
Contracts referencing "the November 2026 deadline" as a single date may no longer describe the operative timeline for every product line. A targeted review of hemp-definition dependencies in supplier, distributor, and retail agreements can prevent disputes once one date has passed and the other has not.
Section 781 is enacted law, and Section 2019 of P.L. 119-103 is now enacted law on top of it. Neither is a proposal, and the December 11 date carries its own risk: it is also the day the continuing resolution's funding expires, so the hemp date rides on the next funding vehicle. Congress could move it again, let it lapse, or leave it as the final word. Operators who segment inventory by cannabinoid origin now are building a compliance position for either outcome. Those who wait for the FDA's overdue cannabinoid list may find it arrives after both deadlines, not before either.
When does the hemp ban take effect?
In two stages. Products containing cannabinoids not capable of being naturally produced by the cannabis plant — THC-O, HHC, and commercial delta-8 THC are the clear cases — lose federal hemp status November 12, 2026. Everything else affected by Section 781, including the total-THC redefinition and the 0.4 mg per-container cap, moves to December 11, 2026 under P.L. 119-103.
Does November 12 still apply to my products?
Yes, for cannabinoids that cannot be naturally produced as sold — including THC-O, HHC, and commercial delta-8 THC. Delta-8 belongs on the November 12 date because virtually all commercially sold delta-8 is manufactured by converting CBD rather than extracted from the plant's trace natural supply; the legal test looks at how the commercial product was actually made, not whether the molecule can theoretically occur in nature. Classification turns on the compound and its documented production route, not the product category — talk to your counsel before relying on either date.
What is the 0.4 mg per container cap?
Starting December 11, 2026, finished hemp-derived cannabinoid products intended for human or animal use may contain no more than 0.4 milligrams of total THC in the innermost container that reaches the consumer. It is a milligram test, not a concentration test, and it counts delta-9, THCA, delta-8, and other THC-class cannabinoids together.
What does the total-THC standard change for THCA products?
The pre-2026 test measured only delta-9 THC. The new test, effective December 11, 2026, measures delta-9 plus 0.877 times THCA, after decarboxylation. THCA flower that passed the old delta-9-only test routinely fails this one, because THCA converts to delta-9 on heating and the statute now counts that conversion up front.
Is federal law the binding deadline in my state?
Not necessarily, and not always in the direction operators expect. Virginia's 2 mg total-THC per-package cap has applied since August 15, 2026 — a stricter and earlier standard than either federal date. Ohio's SB 56 hemp beverage ban, by contrast, has been enjoined for ten named companies while remaining in force for everyone else, splitting the market inside a single state. Check the state date before assuming the federal one controls.
Could Congress still change these dates?
Only by passing another law. Two bills would replace Section 781 with a regulatory framework rather than a ban — the bipartisan Cannabis Administration and Opportunity Act (CAOA) fix and Rep. Andy Barr's Lawful Hemp Protection Act — but as of this writing, neither has moved out of committee. December 11 is also the next government-funding deadline, so a further extension is possible but not guaranteed. Our state-by-state guide to the deadlines that did not move tracks what stays fixed regardless of Congress.
This is regulatory journalism, not legal advice — talk to your counsel.
